<DOC>
	<DOCNO>NCT02330549</DOCNO>
	<brief_summary>A Phase 2a , randomize , double-blind , placebo-controlled , multi-center study CVC conduct approximately 50 adult obese subject ( BMI ≥ 30 kg/m2 ) prediabetes type 2 diabetes mellitus suspect NALFD .</brief_summary>
	<brief_title>ORION : Effects Cenicriviroc Insulin Sensitivity Subjects With Prediabetes T2DM Suspected NAFLD</brief_title>
	<detailed_description>Approximately 50 adult obese subject ( BMI ≥ 30 kg/m2 ) prediabetes type 2 diabetes mellitus suspect NALFD randomize study . Eligible subject receive either CVC ( n=25 ) match placebo ( n=25 ) , daily ( QD ) 24 week , follow safety follow-up visit 4 week last intake study medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Adult male female subject age 1875 year Obesity define BMI ≥ 30 kg/m2 Evidence prediabetes type 2 diabetes mellitus base Screening laboratory value least one follow criterion : Fasting plasma glucose ( FPG ) 100 270 mg/dL ( 5.6 15.0 mmol/L ) Hemoglobin A1c ( HbA1c ) 5.7 10.0 % Subjects receive metformin alone combination sulfonylurea ( glimepiride , glipizide , glyburide , gliclazide ) must stable therapy least 90 day prior Screening . Suspected diagnosis NAFLD warrant confirmation liver biopsy AST ALT ≤ 5 ULN Ability understand sign write informed consent form Females childbearing potential male participate study must agree use least 2 approve barrier method contraception throughout duration study 3 month stop study drug . Females postmenopausal must documentation cessation menses ≥ 12 month serum follicle stimulate hormone ( FSH ) ≥ 30 mU/mL Subjects receive allow concomitant medication need stable therapy 28 day prior Baseline Use OHAs metformin sulfonylurea , include limited thiazolidinediones , DPP4 inhibitor , SGLT2 inhibitor , GLP1 receptor agonist , meglitinides , αglucosidase inhibitor , colesevelam , bromocriptine , pramlintide basal insulin within 90 day prior Screening anticipate use trial Type 1 diabetes HBsAg positive HIV1 HIV2 infection HCVAb positive Prior plan liver transplantation Other know cause chronic liver disease , include alcoholic liver disease History cirrhosis and/or hepatic decompensation include ascites , encephalopathy variceal bleed Alcohol consumption great 14 units/week Weight reduction bariatric surgery plan bariatric surgery conduct study ( include gastric banding ) Any Grade ≥ 3 laboratory abnormality define National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Toxicity Grading Scale , except subject Grade ≥ 3 dyslipidemia triglyceride cholesterol elevation unless clinical assessment foresees immediate health risk subject Serum albumin &lt; 3.5 g/dL Serum creatinine level ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female subject receive metformin Estimated glomerular filtration rate ( eGFR ) &lt; 50 mL/min/1.73 m2 accord Modification Diet Renal Disease ( MDRD ) equation Platelet count &lt; 100,000/mm3 Hemoglobin &lt; 12 g/dL male &lt; 11 g/dL female Females pregnant breastfeed Receiving ongoing therapy disallow medication Screening Allergy study drug component Any clinically significant disorder prior therapy , opinion investigator , would make subject unsuitable study unable comply dose protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>